SG11201509625PA - Methods for treating nasal polyposis by administering an il-4r antagonist - Google Patents

Methods for treating nasal polyposis by administering an il-4r antagonist

Info

Publication number
SG11201509625PA
SG11201509625PA SG11201509625PA SG11201509625PA SG11201509625PA SG 11201509625P A SG11201509625P A SG 11201509625PA SG 11201509625P A SG11201509625P A SG 11201509625PA SG 11201509625P A SG11201509625P A SG 11201509625PA SG 11201509625P A SG11201509625P A SG 11201509625PA
Authority
SG
Singapore
Prior art keywords
antagonist
administering
methods
nasal polyposis
treating nasal
Prior art date
Application number
SG11201509625PA
Inventor
Leda Mannent
Gianluca Pirozzi
Allen Radin
Namita A Gandhi
Robert Evans
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG11201509625PA publication Critical patent/SG11201509625PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG11201509625PA 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist SG11201509625PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837912P 2013-06-21 2013-06-21
EP14305670 2014-05-07
PCT/US2014/043440 WO2014205365A1 (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
SG11201509625PA true SG11201509625PA (en) 2015-12-30

Family

ID=50736018

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201509625PA SG11201509625PA (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist
SG10201710557QA SG10201710557QA (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201710557QA SG10201710557QA (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Country Status (18)

Country Link
US (2) US10059771B2 (en)
EP (2) EP3010539B1 (en)
JP (1) JP6463351B2 (en)
KR (3) KR20230066127A (en)
CN (2) CN105517570B (en)
AU (3) AU2014284235B2 (en)
CA (1) CA2915839A1 (en)
CY (1) CY1122754T1 (en)
HK (1) HK1222567A1 (en)
IL (1) IL243246B (en)
MX (1) MX368068B (en)
PL (1) PL3010539T3 (en)
RS (1) RS59354B1 (en)
RU (1) RU2674680C2 (en)
SG (2) SG11201509625PA (en)
SI (1) SI3010539T1 (en)
TW (2) TWI709411B (en)
WO (1) WO2014205365A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP4324479A3 (en) 2012-08-21 2024-04-24 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
TWI697334B (en) 2013-06-04 2020-07-01 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
HUE046410T2 (en) * 2013-06-21 2020-03-30 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
RS59354B1 (en) 2013-06-21 2019-10-31 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (en) 2013-07-11 2018-09-11 再生元醫藥公司 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
KR20230167770A (en) 2014-02-21 2023-12-11 사노피 바이오테크놀로지 Methods for treating or preventing asthma by administering an il-4r antagonist
ES2973858T3 (en) 2014-02-28 2024-06-24 Regeneron Pharma Methods for treating skin infections by administering an IL-4R antagonist
JP6861630B2 (en) 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー How to treat chronic sinusitis with nasal polyps by administration of IL-4R antagonist
KR20180110089A (en) * 2016-02-19 2018-10-08 리제너론 파아마슈티컬스, 인크. Methods of enhancing the efficacy of a vaccine by administering an IL-4R antagonist
MA46098A (en) * 2016-09-01 2019-07-10 Regeneron Pharma METHODS FOR PREVENTING OR TREATING ALLERGY BY GIVING AN IL-4 R ANTAGONIST
TW202332696A (en) * 2016-12-01 2023-08-16 美商再生元醫藥公司 Methods of treating inflammatory conditions
CN108339118A (en) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 Treat or prevent the pharmaceutical composition of obstructive sleep apnea
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MA46269B1 (en) 2017-08-18 2024-05-31 Regeneron Pharma METHODS OF TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R INHIBITOR
CN111526920A (en) 2017-10-30 2020-08-11 赛诺菲生物技术公司 Methods of treating or preventing asthma by administering IL-4R antagonists
GB201802487D0 (en) * 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
CN108373505B (en) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 Anti- IL-4R antibody and application thereof
BR112020020387A2 (en) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR
EP3878868A4 (en) * 2018-11-09 2022-07-27 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN110746507B (en) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 human interleukin 4 receptor α monoclonal antibody and its application
WO2020180727A1 (en) * 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CN114173819A (en) 2019-08-05 2022-03-11 瑞泽恩制药公司 Methods of treating allergy and enhancing allergen-specific immunotherapy by administering IL-4R antagonists
CN114650828A (en) 2019-09-20 2022-06-21 国立大学法人福井大学 Pharmaceutical composition
BR112022011098A2 (en) 2019-12-09 2022-09-20 Sanofi Biotechnology METHODS FOR TREATMENT OF DIGITALLY IDENTIFIED IL-4/IL-13-RELATED DISORDERS
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
WO2023011502A1 (en) * 2021-08-02 2023-02-09 甘李药业股份有限公司 Stable formulation comprising anti-il-4r antibody

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JP3315427B2 (en) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 Dermatitis treatment
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1304115B1 (en) 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2005032399A2 (en) * 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
CN1886426A (en) 2003-11-07 2006-12-27 伊姆尼斯公司 Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
US7410781B2 (en) 2004-02-27 2008-08-12 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
JP5234445B2 (en) 2004-10-05 2013-07-10 源一郎 杣 Drug
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (en) 2006-10-02 2013-03-20 瑞泽恩制药公司 High affinity human antibodies to human IL-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2604628A3 (en) * 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2271674A2 (en) * 2008-04-02 2011-01-12 Apogenix GmbH Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
US20120004205A1 (en) 2008-12-01 2012-01-05 Cincinnati Children's Hospital Medical Center Il-13 induced gene signature for eosinophilic esophagitis
EP2414520A2 (en) * 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
RU2403071C1 (en) * 2009-09-03 2010-11-10 Логина Наталия Алексеевна Method of treating chronic recurring inflammatory diseases of nasal cavity and paranasal sinises by method of endonasal autolymphocyto therapy
JP5167552B2 (en) * 2010-03-16 2013-03-21 エアソネット・アクチボラゲット Treatment of asthma and allergic rhinitis and improved sleep quality with temperature-controlled laminar airflow therapy
UA111731C2 (en) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. STABILIZED COMPOSITION CONTAINING ANTIBODY TO INTERLAYKIN-4 (IL-4R) RECEPTOR, OPTIONS
MY158130A (en) 2010-10-06 2016-08-30 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
RU2469737C1 (en) * 2011-06-28 2012-12-20 Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Method of treating chronic rhinosinusitis
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
EP4324479A3 (en) 2012-08-21 2024-04-24 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
EP3889181B1 (en) 2012-09-07 2024-04-24 Regeneron Pharmaceuticals, Inc. An il-4r antagonist antibody for use in treating atopic dermatitis by administering
TWI697334B (en) 2013-06-04 2020-07-01 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
RS59354B1 (en) 2013-06-21 2019-10-31 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
KR20230167770A (en) 2014-02-21 2023-12-11 사노피 바이오테크놀로지 Methods for treating or preventing asthma by administering an il-4r antagonist
JP6861630B2 (en) 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー How to treat chronic sinusitis with nasal polyps by administration of IL-4R antagonist

Also Published As

Publication number Publication date
CY1122754T1 (en) 2021-03-12
WO2014205365A1 (en) 2014-12-24
US10059771B2 (en) 2018-08-28
IL243246A0 (en) 2016-03-31
RS59354B1 (en) 2019-10-31
KR20230066127A (en) 2023-05-12
US20190040146A1 (en) 2019-02-07
EP3010539B1 (en) 2019-07-24
AU2019261751B2 (en) 2021-11-25
SI3010539T1 (en) 2019-11-29
AU2014284235B2 (en) 2019-11-21
CN111437387A (en) 2020-07-24
TW202118513A (en) 2021-05-16
EP3613432A1 (en) 2020-02-26
SG10201710557QA (en) 2018-01-30
CA2915839A1 (en) 2014-12-24
RU2016101632A (en) 2017-07-26
TW201534325A (en) 2015-09-16
TWI709411B (en) 2020-11-11
KR20160024916A (en) 2016-03-07
RU2016101632A3 (en) 2018-05-22
MX2015017970A (en) 2016-11-30
MX368068B (en) 2019-09-18
AU2014284235A1 (en) 2016-01-21
IL243246B (en) 2019-09-26
CN105517570A (en) 2016-04-20
RU2674680C2 (en) 2018-12-12
JP6463351B2 (en) 2019-01-30
AU2019261751A1 (en) 2019-11-28
EP3010539A1 (en) 2016-04-27
AU2022201336A1 (en) 2022-03-24
TWI757893B (en) 2022-03-11
US20150017182A1 (en) 2015-01-15
CN105517570B (en) 2020-04-07
JP2016523863A (en) 2016-08-12
PL3010539T3 (en) 2020-01-31
KR20210132232A (en) 2021-11-03
HK1222567A1 (en) 2017-07-07

Similar Documents

Publication Publication Date Title
HK1222567A1 (en) Methods for treating nasal polyposis by administering an il-4r antagonist il-4r
HRP20181963T1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL252228B (en) Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
PT3973987T (en) Methods for treating or preventing asthma by administering an il-4r antagonist
PL3110848T3 (en) Methods for treating skin infection by administering an il-4r antagonist
HRP20182145T1 (en) Antitumor agent including low dose irinotecan hydrochloride hydrate
EP2968458A4 (en) Dosage regimen for therapeutic method
SG10201912898XA (en) Methods for treating nasal polyposis by administering an il-4r antagonist
IL271284A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL285483A (en) Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
IL246913A0 (en) Methods for treating skin infection by administering an il-4r antagonist
IL247290A0 (en) Methods for treating or preventing asthma by administering an il-4r antagonist